

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- ✓ • BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07H 19/06, A61K 31/70		A1	(11) International Publication Number: WO 91/13900 (43) International Publication Date: 19 September 1991 (19.09.91)
<p>(21) International Application Number: PCT/CA91/00077</p> <p>(22) International Filing Date: 13 March 1991 (13.03.91)</p> <p>(30) Priority data: 2,012,093 13 March 1990 (13.03.90) CA 2,012,094 13 March 1990 (13.03.90) CA</p> <p>(71) Applicant (<i>for all designated States except US</i>): ACIC (CANADA) INC. [CA/CA]; 42-46 Spalding Drive, Brantford, Ontario N3T 6B8 (CA).</p> <p>(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>) : KARIMIAN, Khashayar [IR/CA]; 15 Irontate Place, Brantford, Ontario N3R 5V6 (CA).</p>		<p>(74) Agents: NASSIF, Omar, A. et al.; McCarthy Tétrault, P.O. Box 48, Toronto-Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).</p> <p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: PROCESS FOR PRODUCING 2,2'-O-CYCLONUCLEOSIDES, NUCLEOSIDES, AND ANALOGS THEREOF

(57) Abstract

A novel process is provided for producing a nucleoside, such as cytarabine, or a nucleoside analogue, comprising the step of reacting 2,2'-O-cyclonucleoside or an analogue thereof with an amine. Preferably, the process is conducted in the presence of an aqueous solvent. A novel process for the production of the precursor 2,2'-O-cyclonucleoside compounds and pharmaceutically acceptable salts thereof is also provided which comprises reacting a 2,3-O-dialkylstannylene nucleoside compound with an amine in the presence of a sulfonyl compound. Cytarabine is a known antineoplastic and antiviral agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	CN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

PROCESS FOR PRODUCING 2,2'-O-CYCLONUCLEOSIDES,
NUCLEOSIDES, AND ANALOGS THEREOF


TECHNICAL FIELD

5 The present invention relates to a novel process for the production of nucleosides, nucleoside analogues and pharmaceutically acceptable salts thereof which includes, in one aspect of the invention, a novel process for producing cyclonucleosides, specifically 2,2'-o-cyclonucleosides, cyclonucleoside analogues and pharmaceutically
10 acceptable salts thereof.

BACKGROUND ART

Cytarabine, a specific nucleoside compound, is a known antineoplastic and antiviral agent. Cytarabine, which is also known as
15 4-amino-1- β -D-arabino-pentofuranosyl-2(1H)-pyrimidinone, 1- β -D-arabino-pentofuransylcytosine and β -cytosinearabinoside, has the following chemical structure:

20



25

Ogilvie (Carbohydr. Res., 24, 210 (1972)) teaches the production of cytarabine from cytidine. Specifically, the process
30 comprises reacting cytidine with diphenyl carbonate and sodium

-2-

hydrogen carbonate at 150°C in DMF. The product cytarabine was purified using thin layer chromatography and obtained in a yield of 40%.

5 Beranek et al (Nucleic Acid Chemistry, Vol. 1, 249,
Edited by Townsend and Tipson, Wiley, New York) teach the
production of cytarabine from cytidine. Specifically, cytidine is reacted
with incremental amounts of diphenyl carbonate in the presence of DMF
and water at 120°C. The overall yield of pure cytarabine was limited
10 to 31.9%.

Roberts et al (J. Org. Chem., 32, 816 (1967)) teach the
production of cytarabine from cytidine (or from 2'(3')-cytidylic acid).
Specifically, cytidine is reacted with phosphoric acid at 80°C for a
15 period of 30 hours to produce a 2,2'-O-cyclocytidine analogue
intermediate. This intermediate is then hydrolyzed at a pH of 9 utilizing
lithium hydroxide to produce the 3',5'-diphosphate of cytarabine. The
diphosphate is then treated with magnesium chloride, ammonium
chloride and concentrated ammonium hydroxide, and thereafter purified
20 by column chromatography to yield pure cytarabine. The overall yield
of pure cytarabine is limited to 53% based on the unrecovered portion
of the starting cytidine.

Kikugawa et al (J. Org. Chem., 37, 284-288 (1972)) teach
25 the conversion of 2,2'-O-cyclocytidine hydrochloride to cytarabine.
Specifically, ammonia is added to an aqueous solution of 2,2'-O-
cyclocytidine thereby raising the pH to 9. The solution is thereafter
acidified with hydrochloric acid and run through an ion exchange
column. Thereafter, cytarabine is crystallized from ethanol in a yield of
30 90%.

-3-

Sowa et al (Bull. Chem. Soc. Jap., 48, 505-507 (1975)) teach the production of cytarabine from 2,2'-*O*-cyclocytidine. Specifically, sodium hydroxide is added to an aqueous solution of 2,2'-*O*-cyclocytidine hydrochloride thereby raising the pH of the solution to 5 10. Thereafter, the solution is run through a H⁺ ionic exchange resin followed by recrystallization of pure cytarabine from ethanol.

Further, the production of cyclonucleosides is known. For example, Walwick et al (Proc. Chem. Soc., 84 (1959)) teach the 10 production of 2,2'-*O*-cyclocytidine hydrochloride from cytidine. The process involved heating cytidine with polyphosphoric acid followed by dephosphorylation of one of the reaction products, 2,2'-*O*-cyclocytidine-3',5'-diphosphate.

15 Doerr et al (J. Org. Chem., 32, 1462 (1967)) teach the production of 2,2'-*O*-cyclocytidine chloride from uridine using a process comprising six steps. It is interesting to note that in the final step, 2,2'-*O*-cyclocytidine hydrochloride was obtained only in a 57% yield. Taking into account the fact that each step is not quantitative, the overall 20 yield of 2,2'-*O*-cyclocytidine hydrochloride from uridine can be expected to be on the order of from 10% to 20%.

Kikugawa et al (Tet. Lett., 869 (1970)) teach the 25 production of the hydrochloride or the formate salt of 2,2'-*O*-cyclocytidine. Specifically, the process comprises reacting cytidine with thionyl chloride and N,N'-dimethylformamide. It is interesting to note that the crude 2,2'-*O*-cyclocytidine salt was obtained in a yield of only 30.4%. Kikugawa et al (J. Org. Chem., 37, 284 (1972)) also provide an improved process for preparing 2,2'-*O*-cyclocytidine. The

improvement appears to relate to an improved yield (55%) of the product using ion exchange and chromatography techniques.

5 Sowa et al (Bull. Chem. Soc. Jap., 48, 505 (1975)) teach a process for the production of cyclonucleosides which comprises reacting the starting ribonucleoside with thionyl chloride and water and subsequently refluxing the reaction mixture at an acidic pH. It is interesting to note that a yield of about 73% of 2,2'-*O*-cyclocytidine hydrochloride was allegedly obtained whereas a yield of about 47% of
10 2,2'-cyclouridine hydrochloride was allegedly obtained.

15 Yamaguchi et al (J. Med. Chem., 19, 654 (1979)) teach the production of 2,2'-*O*-cyclocytidine hydrochloride via reaction of cytidine with an organic acid chloride.

The aforementioned prior art techniques for the preparation of 2,2'-cyclonucleosides are deficient in that they require multiple steps with inherent loss of yield and/or they require silica/resin columns for isolation and purification. Furthermore, the prior art processes for the
20 production of cytarabine and its analogues are deficient in that the purified product is obtained in a relatively low yield and/or the process is complicated requiring a series of steps including the use of ion exchange resins.

25 It would be desirable to have a relatively simple process for producing 2,2'-*O*-cyclonucleosides in acceptable and/or comparable yields. Furthermore, it would be desirable to have a process for the production of 2,2'-*O*-cyclonucleosides such as cytarabine and pharmaceutically acceptable salts thereof in relatively high yields and by
30 a relatively simple process.

-5-

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a novel process for the production of nucleosides, nucleoside analogues and
5 pharmaceutically acceptable salts thereof.

It is another object of the present invention to provide a novel process for the production of cytarabine, cytarabine analogues and pharmaceutically acceptable salts thereof.

10

It is another object of the present invention to provide a novel process for the production of 2,2'-O-cyclonucleoside compounds and pharmaceutically acceptable salts thereof.


15

It is yet another object of the present invention to provide a novel process for the production of 2,2'-O-cyclocytidine compounds and pharmaceutically acceptable salts thereof.

20

Accordingly, the present invention provides a process for directly preparing a compound of Formula I, or a pharmaceutically acceptable salt thereof:

25




30

-6-

which comprises the step of reacting (i) a compound of Formula II or a pharmaceutically acceptable salt thereof:

5



10

wherein R^1 is selected for the group comprising hydrogen, trityl, methoxytrityl, dimethoxytrityl, acetyl, a C_2 - C_6 alkylacyl group, a C_6 - C_9 arylacyl group, allyl, 2,2,2-trichloroethyl, phosphates and salts thereof, 15 tosyl and mesyl; W is selected from the group comprising -NH-CO- and -NH-C(NH₂)-; Z is selected from the group comprising hydrogen and methyl; and Y is selected from the group comprising -N(H)- or O; with (ii) an amine selected from the group comprising C_5 - C_{12} heterocyclic amines and amines having the general formula

20



25


wherein R^2 , R^3 and R^4 can be the same or different and are selected from the group comprising hydrogen, a C_1 - C_6 alkyl group and a C_6 - C_9 aryl group, with the proviso that the each of R^2 , R^3 and R^4 is not hydrogen.

In another aspect of the present invention a process for producing a compound of Formula II:

30


-7-

5




or a pharmaceutically acceptable salt thereof is provided which
10 comprises the step of reacting (i) a compound of Formula III:

15



20 wherein R¹, W and Z are as defined above and R⁵ is a C₁-C₆ alkyl group, with (ii) an amine selected from pyridine and amines having the general formula



25

wherein Q², Q³ and Q⁴ can be the same or different and are selected from the group comprising a C₁-C₆ alkyl group and a C₆-C₉ aryl group, in the presence of (iii) a sulfonyl compound having the general formula

30



-8-


wherein R^6 is selected from the group comprising $-CF_3$, a C_1 - C_6 alkyl group and C_6 - C_9 aryl group, and X is selected from a halogen and SO_3CF_3 , to produce a compound of Formula II.

5

In another aspect of the present invention a process for producing a compound of Formula II:

10

15




wherein Y is $-N(H)-$ and Z is hydrogen, or a pharmaceutically acceptable salt thereof, is provided which comprises the step of reacting

(i) a compound of Formula III:

20

25



wherein R^1 is as defined above, W is $-NH-C(NH_2)$, Z is hydrogen and R^5 is a C_1 - C_6 alkyl group, with (ii) an amine selected from pyridine and amines having the general formula

30

-9-

 $Q^2Q^3Q^4N$


wherein Q^2 , Q^3 and Q^4 can be the same or different and are selected from the group comprising a C_1 - C_6 alkyl group and a C_6 - C_9 aryl group,
 5 in the presence of (iii) a sulfonyl compound having the general formula

 R^6SO_2X

wherein R^6 is selected from the group comprising $-CF_3$, a C_1 - C_6 alkyl group and C_6 - C_9 aryl group, and X is selected from a halogen and SO_3CF_3 , to produce a compound of Formula II.

In yet another aspect of the present invention, a process is provided for preparing a compound of Formula I, or a pharmaceutically acceptable salt thereof:
 15

20




25

which comprises the step of reacting (i) a compound of Formula III:


30

-10-

5



with (ii) an amine selected from pyridine and amines having the general
10 formula



wherein Q², Q³ and Q⁴ can be the same or different and are selected
from the group comprising a C₁-C₆ alkyl group and a C₆-C₉ aryl group,
15 in the presence of (iii) a sulfonyl compound having the general formula



wherein R⁶ is selected from the group comprising -CF₃, a C₁-C₆ alkyl
20 group and C₆-C₉ aryl group, and X is selected from a halogen and
-SO₃CF₃, to produce a compound of Formula II, and reacting a
compound of Formula II or a pharmaceutically acceptable salt thereof
with (iv) an amine selected from the group comprising C₅-C₁₂
heterocyclic amines and amines having the general formula

25



wherein R², R³ and R⁴ are as defined above.

30


-11-

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The compound of Formula II:

5

10



is known. Compounds of Formula II may be prepared in a number of manners; however, preferably, this compound is prepared by reacting a tin oxide conjugate of Formula III. It will of course be understood that 15 the manner in which starting compound of Formula III is made is not particularly restricted as regards the process for making compounds of Formula II.

Preferably, the process for producing a compound of 20 Formula II can be used to produce 2,2'-*O*-cycloribonucleosides such as 2,2'-*O*-cyclocytidine, 2,2'-*O*-cyclouridine, 2,2'-*O*-cyclothymidine, or pharmaceutically acceptable salts thereof. Generally, 2,2'-*O*-cycloribonucleosides may be prepared by reacting the appropriate nucleoside with the appropriate dialkyl tin oxide. More preferably, this 25 process is used to produce 2,2'-*O*-cyclocytidine by reacting a cytidine-compound-tin oxide conjugate of Formula III in which W is -N=C(NH₂)- and Z is hydrogen.

In one preferred embodiment of the invention, in which the 30 compound of Formula III is a cytidine conjugate, R⁵ is butyl and R¹ is

-12-

hydrogen. With these definitions for R⁵ and R¹, the compound of Formula III is 2',3'-O-dibutylstannylene cytidine.

An example of a suitable "C₂-C₆ alkylacyl group" for use 5 as R¹ is acetyl. Further, an example of a suitable "C₆-C₉ arylacyl group" for use as R¹ is benzoyl.

Provided that it does not contain a hydrogen bonded to 10 nitrogen, the amine suitable for use in the process for producing a compound of Formula II is not particularly restricted and may be selected from the group comprising trimethylamine, triethylamine, pyridine, tripropylamine and tributylamine. The most preferred amine is triethylamine.

15 The reaction of a compound of Formula III with the amine is conducted in the presence of a sulfonyl compound, preferably a sulfonyl chloride compound. More preferably the sulfonyl chloride compound is one of p-toluenesulfonyl chloride and methanesulfonyl chloride.

20 Typically, the above-noted reaction can be conducted at room temperature, preferably with agitation of the reaction mixture (such as stirring). The reaction may be conducted in any suitable organic solvent system. Examples of suitable organic solvents include: 25 alcohols, toluene, benzene, chloroform, dichloromethane and the like. The preferred organic solvents are alcohols, more preferably methanol.

30 The most preferred starting material of Formula II for the process of producing a compound of Formula I is 2,2'-O-cyclocytidine in which R¹ of Formula II is hydrogen. In this embodiment, the product

-13-

of Formula I is cytarabine. It will of course be understood that the manner in which starting compound of Formula II is made is not particularly restricted as regards the process of making Formula I.

5 The amine suitable for use in the process of producing a compound of Formula I is selected from the group comprising C₅-C₁₂ heterocyclic amines and amines having the general formula



10 wherein R², R³ and R⁴ can be the same or different and are selected from the group comprising hydrogen, a C₁-C₆ alkyl groups and a C₆-C₉ aryl group, with the proviso that each of R², R³ and R⁴ is not hydrogen. Thus, it will be appreciated that the use of ammonia (i.e. R² = R³ = R⁴ = H) is outside the scope of the present invention. Non-limiting examples of suitable heterocyclic amines include pyridine and piperidine. Non-limiting examples of other amines suitable for use include t-butylamine, trimethylamine, triethylamine, tripropylamine, tributylamine, methylamine, ethylamine, diethylamine and aniline. The 15 most preferred amine suitable for use in the present process is t-butylamine.

20 Preferably, the process of producing a compound of Formula I is conducted in the presence of an aqueous solvent. Examples 25 of suitable aqueous solvents include water and a mixture of water and at least one other solvent miscible therewith. The most preferred aqueous solvent for use in this process comprises solely water.

30 Typically, the reaction used to produce a compound of Formula I can be conducted at room temperature, preferably with

-14-

agitation (such as stirring) of the reaction mixture. The reaction may be conducted in any polar solvent for the starting compound of Formula I. Preferably, the solvent is water.

5 The crude 2,2'-*O*-cyclonucleoside precursor product, preferably, 2,2'-*O*-cyclocytidine, as well as the crude final products, preferably, cytarabine, cytarabine analogues or pharmaceutically acceptable salts thereof, may be separated from the reaction mixture and purified using conventional techniques within the purview of a person skilled in the art. For example, after the reaction is complete, the solvents may be evaporated under vacuum. Crude 2,2'-*O*-cyclonucleoside may be suspended and refluxed in a suitable medium (e.g. chloroform). Thereafter, the crude 2,2'-*O*-cyclonucleoside may be purified from water (in which the product is soluble) and alcohol (in which the product is relatively insoluble). The resulting final cytarabine solid may be suspended and agitated in a suitable medium to produce a purified product. Examples of such media include alcohol and mixtures containing alcohol and water. The preferred alcohol for use is ethanol.

20 Aspects of the present invention will be described with reference to the following Examples which should not be considered to limit the scope of the invention.

25 **EXAMPLE 1**

A 500 mL flask was charged with 50 mL methanol, 1.95 g cytidine and 2 g dibutyl tin oxide. The resulting suspension was refluxed for five hours and then stirred at room temperature for twelve hours. To the mixture was then added triethylamine (7.8 mL) followed by slow addition of p-toluenesulfonyl chloride (10.68 g). The resulting

-15-

mixture was stirred for twelve hours at room temperature. Thereafter, the solvents were evaporated under vacuum and chloroform (100 mL) was added to the resulting white gum. The chloroform/white gum suspension was refluxed for fifteen minutes and then cooled to room
5 temperature. The resulting white precipitate was filtered and washed with chloroform, and dried to yield 1 g of crude 2,2'-*O*-cyclocytidine hydrochloride. The crude cyclocytidine hydrochloride was suspended in 5 mL water and the mixture was heated to 60°C. This solution was filtered and the solvent reduced under vacuum to obtain a turbid oil.
10 Ethanol (18 mL) was added and the mixture was stirred at 5°C for twelve hours. The resulting precipitate was filtered and dried to provide 0.6 g of pure 2,2'-*O*-cyclocytidine hydrochloride (29% yield). The product was characterized by comparison of its melting point, and NMR and IR spectra with those previously reported for 2,2'-*O*-cyclocytidine.

15

EXAMPLE 2

2,2'-*O*-cyclocytidine hydrochloride (6.5 g) was dissolved in 35 mL water at 80°C. The solution was cooled to room temperature
20 and t-butylamine (2.8 g) was added and the mixture stirred for 2 hours. Thereafter, the solvent was evaporated under vacuum and ethanol (16 g) was added. The mixture was stirred at room temperature for 12 hours. Filtration of the resulting precipitation yielded 5 g of pure cytarabine after drying, which corresponds to a yield of 83%. The product was
25 characterized by comparison of its melting point, and NMR and IR spectra with those previously reported for cytarabine.


-16-

What is claimed is:

1. A process for directly preparing a compound of Formula I, or a pharmaceutically acceptable salt thereof:

5

10




15

- which comprises the step of reacting (i) a compound of Formula II or a pharmaceutically acceptable salt thereof:

20

25



wherein R¹ is selected from the group comprising hydrogen, trityl, methoxytrityl, dimethoxytrityl, acetyl, a C₂-C₆ alkylacyl group, allyl, 2,2,2-trichloroethyl, phosphates and salts thereof, tosyl and mesyl; W is selected from the group comprising -NH-CO- and -NH-C(NH₂)-;

-17-

Z is selected from the group comprising hydrogen and methyl; and Y is selected from the group comprising -N(H)- or O, with (ii) an amine selected from the group comprising C₅-C₁₂ heterocyclic amines and amines having the general formula

5



wherein R², R³ and R⁴ can be the same or different and are selected from the group comprising hydrogen, a C₁-C₆ alkyl group and a C₆-C₉ 10 aryl group, with the proviso that each of R², R³ and R⁴ are not hydrogen.

2. The process defined in claim 1, wherein R¹ is hydrogen.
- 15 3. The process defined in claim 1, wherein said amine is selected from the group comprising t-butylamine, trimethylamine, triethylamine, pyridine, tripropylamine, tributylamine, methylamine, ethylamine, diethylamine, aniline and piperidine.
- 20 4. The process defined in claim 2, wherein the amine is t-butylamine.
5. The process defined in claim 1, wherein said step is conducted in the presence of an aqueous solvent.
- 25 6. The process defined in claims 2, 3 or 4, wherein said step is conducted in the presence of an aqueous solvent selected from water and a mixture of water with at least one other solvent miscible therewith.


30

-18-

7. The process defined in claim 4, wherein said step is conducted in the presence of an aqueous solvent comprising solely water.


5 8. A process for producing a compound of Formula II as defined in claim 1, or pharmaceutically acceptable salt thereof, which comprises the step of reacting (i) a compound of Formula III:

10



15

wherein R⁵ is a C₁-C₆ alkyl group and R¹, W and Z have the same meanings as in claim 1, with (ii) an amine selected from pyridine and
20 amines having the general formula



wherein Q², Q³ and Q⁴ can be the same or different and are selected
25 from the group comprising a C₁-C₆ alkyl group and a C₆-C₉ aryl group,
in the presence of (iii) a sulfonyl compound having the general formula



-19-

wherein R⁶ is selected from the group comprising -CF₃, a C₁-C₆ alkyl group and C₆-C₉ aryl group, and X is selected from -SO₃CF₃ and a halogen, to produce a compound of Formula II.

5 9. The process defined in claim 8, wherein R¹ is hydrogen.

10. The process defined in claim 8, wherein X is chloride.

11. The process defined in claim 9, wherein said sulfonyl
10 compound is selected from p-toluenesulfonyl chloride and methanesulfonyl chloride.

12. The process defined in claim 9, wherein said sulfonyl compound is p-toluenesulfonyl chloride.

15 13. The process defined in claims 8, 9, 10 or 11, wherein said amine is selected from the group comprising trimethylamine, triethylamine, pyridine, tripropylamine and tributylamine.

20 14. The process defined in claim 12, wherein said amine is triethylamine.

15. The process defined in claims 8, 9, 10 or 11, wherein said step is conducted in the presence of an organic solvent.


25 16. The process defined in claims 8, 9, 10 or 11, wherein said step is conducted in the presence of an organic solvent selected from the group comprising alcohols, toluene, benzene, chloroform and dichloromethane.

-20-

17. The process defined in claim 14, wherein said step is conducted in the presence of methanol.

18. A process for preparing a compound of Formula I, or a
5 pharmaceutically acceptable salt thereof:

10




15

which comprises the step of reacting (i) a compound of Formula III:

20

25



30

-21-

wherein R¹ is selected from the group comprising hydrogen, trityl, methoxytrityl, dimethoxytrityl, acetyl, a C₂-C₆ alkylacyl group, allyl, 2,2,2-trichloroethyl, phosphates and salts thereof, tosyl and mesyl; W is selected from the group comprising -NH-CO- and -NH-C(NH₂)-; 5 and Z is selected from the group comprising hydrogen and methyl, with (ii) an amine selected from pyridine and amines having the general formula

Q²Q³Q⁴N

10

wherein Q², Q³ and Q⁴ can be the same or different and are selected from the group comprising a C₁-C₆ alkyl group and a C₆-C₉ aryl group, in the presence of (iii) a sulfonyl compound having the general formula


15

R⁶SO₂X

wherein R⁶ is selected from the group comprising -CF₃, a C₁-C₆ alkyl group and C₆-C₉ aryl group, and X is selected from a halogen and -SO₃CF₃, to produce a compound of Formula II:

20

25



30

-22-

wherein Y is selected from the group comprising -N(H)- and O, and reacting a compound of Formula II or a pharmaceutically acceptable salt thereof with (iv) an amine selected from the group comprising C₅-C₁₂ heterocyclic amines and amines having the general formula

5




wherein R², R³ and R⁴ can be the same or different and are selected from the group comprising hydrogen, a C₁-C₆ alkyl group and a C₆-C₉ aryl group, with the proviso that each of R², R³ and R⁴ are not hydrogen.

- 10 19. The process defined in claim 18, wherein R¹ is hydrogen.
- 15 20. The process defined in claim 18, wherein the reaction to produce a compound of Formula II is conducted in the presence of an organic solvent, and the subsequent reaction to form a compound of Formula I is conducted in the presence of an aqueous solvent.
- 20 21. The process defined in claim 18, wherein the amine used in step (ii) is selected from the group comprising trimethylamine, triethylamine, pyridine, tripropylamine and tributylamine and the amine used in step (iv) is selected from the group comprising t-butylamine, trimethylamine, triethylamine, pyridine, tripropylamine, tributylamine, 25 methylamine, ethylamine, diethylamine, aniline and piperidine.
22. The process defined in claim 21, wherein the amine used in step (ii) is triethylamine and the amine used in step (iv) is t-butylamine.

-23-

23. The process defined in claim 18, wherein X is chloride.
24. The process defined in claim 18, wherein said sulfonyl compound is selected from p-toluenesulfonyl chloride and methanesulfonyl chloride.
- 5 25. A process for producing a compound of Formula II

10




15

wherein Y is -N(H)- and Z is hydrogen, or a pharmaceutically acceptable salt thereof, which comprises the step of reacting (i) a compound of Formula III:

20

25




wherein R¹ is selected from the group comprising hydrogen, trityl, methoxytrityl, dimethoxytrityl, acetyl, a C₂-C₆ alkylacyl group, allyl,

-24-

2,2,2-trichloroethyl, phosphates and salts thereof, tosyl and mesyl, W is -NH-C(NH₂)-, Z is hydrogen and R⁵ is a C₁-C₆ alkyl group, with (ii) an amine selected from pyridine and amines having the general formula

5



wherein Q², Q³ and Q⁴ can be the same or different and are selected from the group comprising a C₁-C₆ alkyl group and a C₆-C₉ aryl group, in the presence of (iii) a sulfonyl compound having the general formula

10



wherein R⁶ is selected from the group comprising -CF₃, a C₁-C₆ alkyl group and C₆-C₉ aryl group, and X is selected from a halogen and

15



26. The process defined in claim 25, wherein R¹ is hydrogen.

27. The process defined in claim 25, wherein X is chloride.

20

28. The process defined in claim 26, wherein said sulfonyl compound is selected from p-toluenesulfonyl chloride and methanesulfonyl chloride.

25

29. The process defined in claim 26, wherein said sulfonyl compound is p-toluenesulfonyl chloride.

30. The process defined in claims 25, 26, 27 or 28, wherein said amine is selected from the group comprising trimethylamine, triethylamine, pyridine, tripropylamine and tributylamine.

-25-

31. The process defined in claim 29, wherein said amine is triethylamine.
32. The process defined in claims 25, 26, 27 or 28, wherein
5 said step is conducted in the presence of an organic solvent.
33. The process defined in claims 25, 26, 27 or 28, wherein
said step is conducted in the presence of an organic solvent selected
from the group comprising alcohols, toluene, benzene, chloroform and
10 dichloromethane.
34. The process defined in claim 31, wherein said step is
conducted in the presence of methanol.
- 15 35. The process defined in claim 1, wherein Y is -N(H)- and
Z is hydrogen.
36. The process defined in claim 8, wherein W is -NHC(NH₂)-
and Z is hydrogen.
20
37. The process defined in claim 18, wherein W is
-NHC(NH₂)- and Z is hydrogen.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 91/00077

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: C 07 H 19/06, A 61 K 31/70

II. FIELDS SEARCHED

Minimum Documentation Searched †

Classification System	Classification Symbols
IPC ⁵	C 07 H 19/00, A 61 K 31/00

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched §

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages ††	Relevant to Claim No. ††
Y	The Journal of Organic Chemistry, vol. 39, no. 1, 11 January 1974 D. Wagner et al.: "Preparation and synthetic utility of some organotin derivatives of nucleosides", pages 24-30, see the whole document, but especially abstract; page 24, column 1, lines 1-30; page 25, column 1, line 60 - column 2, line 5; Page 26, column 2, lines 10-24 --	1-37
Y	Chemical Abstracts, vol. 86, no. 16, 18 April 1977, (Columbus, Ohio, US) see page 583, abstract no. 121712t & JP, A, 76113881 (MITSUI SEIYAKU KOGYO CO. LTD) 7 October 1976 --	1-37
Y	US, A, 4652554 (T.L. CHWANG) 24 March 1987 see column 4, line 55 - column 5, line 6; especially lines 60,61 --	1-37 . / .

* Special categories of cited documents: ††

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search
31st May 1991

Date of Mailing of this International Search Report

29.07.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Mme. M. van der Drift
Mme. M. van der Drift

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	<p>Tetrahedron Letters, no. 29, 1966, Pergamon Press Ltd. (GB) H.P.M. Fromageot et al.: <u>N⁴,O^{3'},O^{5'}-triacetyl-2,2'-anhydro-</u> <u>cytidine, A postulated reactive</u> <u>intermediate in a convenient</u> <u>synthesis of 1-beta-D-arabino-</u> <u>furanosylcytosine", pages 3499-</u> <u>3305, see the whole document,</u> <u>especially page 3500, lines 6,7;</u> <u>page 3501, lines 20-25</u></p> <p>-----</p>	1-37

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

**CA 9100077
SA 45256**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 16/07/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4652554	24-03-87	None	